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Besides its classical function of bone
metabolism regulation, vitamin D exhibits
multiple biological targets mediated by
its nuclear hormone receptor, the vitamin
D receptor (VDR) (Holick, 2007; Kalu-
eff and Tuohimaa, 2007; Annweiler et al.,
2010a, 2011b). Specific actions on tar-
get organs such as the central nervous
system (CNS) have been described, pro-
viding evidence for a neurosteroid action
of vitamin D (Kalueff and Tuohimaa,
2007; Annweiler et al., 2010a). Consis-
tently, older adults with lower serum
25-hydroxyvitamin D (25OHD) concen-
trations exhibit more often and more
severe cognitive decline (Annweiler et al.,
2009, 2013a,b; Balion et al., 2012; Etgen
et al., 2012). At that point, an impor-
tant issue to be clarified is to deter-
mine what concentration of 25OHD is
associated with adverse effects in the
brain.
MOST OLDER ADULTS HAVE LOW
LEVELS OF VITAMIN D
At least one billion people have hypovita-
minosis D worldwide (Holick, 2007). Even
if all adults can be affected by hypovita-
minosis D, older adults have the greatest
risk, especially those living in institution
(Annweiler et al., 2011b). For illustration,
in Europe and the United States, up to 90%
of older adults have hypovitaminosis D
(Annweiler et al., 2011b). This high preva-
lence of hypovitaminosis D in the elderly
is due to the high frequency of mecha-
nisms leading to hypovitaminosis D, first
and foremost the reduction of cutaneous
synthesis (decreased exposure to sunlight
due to loss of functionality, and decreased
capacity of skin synthesis due to the 25%
reduction of 7-dehydrocholesterol com-
pared to younger adults) (Holick et al.,
1989). Hypovitaminosis D may also result
from the alteration of the metabolism
of vitamin D (hepatic and kidney fail-
ures) (Dusso et al., 2005), inadequate food
intake (Hollis and Wagner, 2004), reduced
bioavailability (malabsorption syndrome,
obesity with sequestration of vitamin D in
the fat) (Lo et al., 1985), increased catab-
olism (regular use of antiepileptics, glu-
cocorticoids, immunosuppressive drugs)
(Zhou et al., 2006), and urinary loss of vita-
min D (nephrotic syndrome) (Dusso et al.,
2005).
The high prevalence of hypovitaminosis
D in elderly population is also explained
by the choice of the threshold defin-
ing hypovitaminosis D, which may vary
between 10 and 30 ng/mL.
THRESHOLD OF “NORMALITY” FOR
SERUM VITAMIN D CONCENTRATION
Vitamin D status is usually estimated by
measuring serum 25OHD (Holick, 2007;
Annweiler et al., 2011b). In general, there
are two ways to establish reference val-
ues for a biological variable. The first one
is based on the use of “population-based
reference values,” which comprises mea-
suring a parameter in the reference pop-
ulation size and calculating the reference
interval in which there is 95% of the pop-
ulation. In the case of 25OHD, the ref-
erence values could not be generalized
because they depend on non-modifiable
environmental factors (e.g., season, local
climate, latitude), modifiable life habits
(e.g., clothing, eating habits, sun exposure),
and non-modifiable parameters (e.g., eth-
nicity, skin pigmentation, skin thickness,
and age). Moreover, it should be kept in
mind that, in clinical practice, the dosage
of 25OHD is prescribed to determine if
patients need vitamin D supplementa-
tion to maintain their health. These val-
ues have therefore little interest for the
clinicians.
The second method for calculating ref-
erence values of 25OHD is to define
hypovitaminosis D as 25OHD levels for
which there are some adverse health effects.
These reference values are called “health-
based reference values.” There is an inter-
national consensus to use this kind of
threshold in the case of 25OHD (Annweiler
et al., 2011b). The determination of such
a threshold remains yet complex because
of the multiplicity of disorders caused
by hypovitaminosis D. Thus, historically,
“normality” was defined by the avoid-
ance of bone adverse effects. It is clas-
sically recognized that there is no rick-
ets or osteomalacia with serum 25OHD
above 10 ng/mL (Basha et al., 2000), and
no secondary hyperparathyroidism with
serum 25OHD above 20 ng/mL (Basha
et al., 2000). For now, the threshold
at 10 ng/mL (25 nmol/L) remains con-
sensual to define vitamin D deficiency
(i.e., severe hypovitaminosis D) (Holick,
2007; Annweiler et al., 2011b), and the
threshold at 20 ng/mL (50 nmol/L) is the
one used by the World Health Orga-
nization to define vitamin D insuffi-
ciency (World Health Organization, 2003).
However, more recently, it has been
elegantly reported that serum 25OHD
above 30 ng/mL (75 nmol/L) is required
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to prevent a number of non-bone effects
(Bischoff-Ferrari et al., 2006).
However, it is not clear thus far which
of these thresholds matches the eviction
of neurological adverse effects of hypovita-
minosis D. This would require confronting
these three thresholds with the neurolog-
ical effects that have been described in
relation to vitamin D.
VITAMIN D AND THE CENTRAL
NERVOUS SYSTEM: PRECLINICAL
EVIDENCE
Vitamin D is able to enter the cerebrospinal
fluid (CSF) and brain by crossing the
blood–brain barrier via passive diffusion
and additional specific carriers in the cere-
bral capillaries or the blood–CSF barrier
in the plexus choroideus (Holmøy et al.,
2009). The concentration of 25OHD in
the CSF positively correlates with that in
the serum under physiological conditions
(Holmøy et al., 2009). In situ, vitamin
D exerts most of its actions through its
nuclear hormone receptor, VDR, expressed
in neuronal and glial cells of the CNS,
especially the hippocampus, hypothala-
mus, cortex, and subcortex (Kalueff and
Tuohimaa, 2007; Annweiler et al., 2010a).
The binding of vitamin D on the VDR
triggers neuronal protection against sev-
eral degenerative processes, including anti-
inflammatory action (Moore et al., 2005),
antioxidant effect (Ibi et al., 2001), con-
trol of calcium homeostasis by regulating
the concentration of intracellular calcium
in hippocampal neurons (Brewer et al.,
2001), anti-atrophic effect by regulating
neurotrophic agents (Brown et al., 2003),
and attenuation of Aβ42 peptide accu-
mulation (Yu et al., 2011) by stimulating
the phagocytosis of Aβ peptide (Masoumi
et al., 2009) together with enhancing brain-
to-blood Aβ efflux transport at the blood–
brain barrier (Ito et al., 2011). More-
over, vitamin D regulates the genetic
expression of numerous neurotransmit-
ters in the brain, including acetylcholine,
dopamine, serotonin, and γ-aminobutyric
acid, notably in the hippocampus (Kalu-
eff and Tuohimaa, 2007). These experi-
mentally described neurosteroid properties
of vitamin D may help, in the case of
normalized vitamin D status, to address
against the decline of brain function in
older adults, especially against cognitive
decline (Annweiler and Beauchet, 2011).
VITAMIN D AND COGNITION:
EPIDEMIOLOGICAL EVIDENCE
Most studies on this topic have been con-
ducted in the past decade. It has become
clear that older adults with Alzheimer’s
disease have lower vitamin D concentra-
tions than others (Balion et al., 2012;
Annweiler et al., 2013a). Similarly, hypovi-
taminosis D is associated with the pres-
ence of dementia in cross-sectional stud-
ies (Buell et al., 2010). Prospective lon-
gitudinal cohorts in older adults have
also reported that hypovitaminosis D pre-
dicted increased incidence of dementia
after 7 years of follow-up (Annweiler et al.,
2011a). In contrast, high dietary intake of
vitamin D (≥800 UI/day reduced the inci-
dence of Alzheimer’s disease after 7 years
(Annweiler et al., 2012a). The relationship
between vitamin D and dementia is high-
lighted during the advanced stages of the
disease (Annweiler et al., 2011), but also
from the prodromal stage (mild cogni-
tive impairment, MCI) (Annweiler et al.,
2012b) even though this minor neurocog-
nitive disorder does not diminish the func-
tional autonomy. Finally, the relationship
between vitamin D and cognition was also
found in people without dementia, with a
linear relationship (Annweiler et al., 2009).
The lower the concentration of vitamin
D, the more impaired the cognitive per-
formance (Oudshoorn et al., 2008). This
direct association was found with both the
global cognitive performance (Etgen et al.,
2012), the memory, and especially with
the executive functions (Annweiler et al.,
2013b). In other words, vitamin D is asso-
ciated with cognitive performance in older
adults even before the onset of dementia.
It is thus crucial to appreciate, in older
adults with or without dementia, what level
of vitamin D is associated with impaired
cognitive scores.
ANALYTICAL STUDY OF THE
THRESHOLD OF SERUM 25OHD
CONCENTRATION RELATED TO
COGNITIVE DISORDERS
Table 1 summarizes the characteristics of
the studies that have explored the asso-
ciation of cognitive scores with hypovi-
taminosis D defined as serum 25OHD
concentration less than either 10, 20, or
30 ng/mL.
As illustrated, the results were mixed,
with some studies having found an
association between hypovitaminosis D
and cognitive disorders (Wilkins et al.,
2006; Buell et al., 2009; Annweiler et al.,
2010b; Llewellyn et al., 2010, 2011; Hansen
et al., 2011; Menant et al., 2012; Slinin et al.,
2012), while others reported no associa-
tion (Aung et al., 2006; Buell et al., 2009;
Wilkins et al., 2009; Hansen et al., 2011;
Menant et al., 2012). Of note, it was pri-
marily the threshold at 10 ng/mL that was
associated with cognition, whereas this was
not the case with the threshold at 20 ng/mL.
Additionally, the convincing results with
the threshold at 30 ng/mL were constantly
found in comparison with concentrations
lower than 10 ng/mL, which reinforces the
clinical value of the latter threshold with
respect to cognition.
Highlighting that the threshold of
25OHD at 10 ng/mL is linked to cogni-
tion makes sense. Indeed, the brain is
able to withstand degenerative lesions for
a long time before expressing an objecti-
fied cognitive decline (Jack et al., 2010).
In other words, occurrence of cognitive
disorders means that the brain is already
the seat of advanced neuronal damages.
Precisely, since hypovitaminosis D occurs
gradually, presenting with 25OHD concen-
tration lower than 10 ng/mL means that
hypovitaminosis D is chronic (Annweiler
et al., 2011b), and has probably led to brain
dysfunction for a long time. In line with
this, it has already been shown that the
lower the 25OHD concentration, the more
severe the chronic diseases (Beauchet et al.,
2012).
IMPLICATIONS FOR PRACTICE AND
RESEARCH
The existing body of evidence provides
proof that the threshold of 25OHD asso-
ciated with cognitive status is around
10 ng/mL, the people with 25OHD con-
centration <10 ng/mL having a greater
risk of cognitive disorders than those with
25OHD >10 ng/mL, and an even greater
risk compared to those with 25OHD
>30 ng/mL. The implications for practice
and research are manifold. First, this find-
ing supports the idea that chronic hypovi-
taminosis D is a risk factor for cognitive
disorders, and may partially explain the
onset of dementia among older adults. Sec-
ond, it means that older adults with cogni-
tive disorders likely have very low 25OHD
concentrations and, thus, should receive
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Table 1 | Summary of the observational studies examining the association between cognitive scale scores and hypovitaminosis D using a
threshold at 10, 20, or 30ng/mL.
Reference Settings Population Subgroups of serum
25-hydroxyvitamin D
Association with cognitive
scale scores?
THRESHOLD 10ng/mL
Wilkins et al.
(2006)
Location: Washington, DC,
USA (38.9°N)
Community-dwellers <10 Versus ≥20 ng/mL Yes, with global cognitive
performanceN =80, 62.5% women
Mean age: 74.8±7.7 years
22.5% Black
Specificity: half with mild dementia,
and half without dementia
Aung et al. (2006);
CREST study
Location: Harris County, TX,
USA (29.8°N)
Community-dwellers <10 Versus ≥10 ng/mL No, with global cognitive
performance
No, with executive functions
N =44, 63.6% women
Mean age: 76.1 years
38.6% White
Specificity: self-neglecting older adults
referred by the adult protective
services
Buell et al. (2009);
NAME study
Location: Boston, MA, USA
(42.2°N)
Community-dwellers <10 Versus
10–20 ng/mL
No, with global cognitive
performanceN =1080, 75.9% women
Mean age: 75.0±8.5 years
34.9% Black
Specificity: older adults receiving
home health services
No, with information
processing speed
Yes, with mental shifting
Yes, with information updating
Annweiler et al.
(2010b); EPIDOS
study
Location: France (Toulouse,
43.4°N; Montpellier, 43.6°N;
Lyon, 45.5°N; Paris 48.5°N;
Amiens, 49.9°N)
Community-dwellers <10 Versus ≥10 ng/mL Yes, with global cognitive
performanceN =752, 100% women
Mean age: 81.2±3.5 years
Specificity: only older women
THRESHOLD 20ng/mL
Wilkins et al.
(2006)
Location: Washington, DC,
USA (38.9°N)
Community-dwellers 10–19.9 Versus
≥20 ng/mL
Yes, with global cognitive
performanceN =80, 62.5% women
Mean age: 74.8±7.7 years
22.5% Black
Specificity: half with mild dementia,
and half without dementia
Aung et al. (2006);
CREST study
Location: Harris County, TX,
USA (29.8°N)
Community-dwellers <20 Versus ≥20 ng/mL No, with global cognitive
performance
No, with executive functions
N =44, 63.6% women
Mean age: 76.1 years
Specificity: self-neglecting older adults
referred by the adult protective
services
Buell et al. (2009);
NAME study
Location: Boston, MA, USA
(42.2°N)
Community-dwellers
N =1080, 75.9% women
Mean age: 75.0±8.5 years
34.9% Black
10–20 Versus
>20 ng/mL
Yes, with global cognitive
performance
No, with information
processing speed
No, with mental shifting
No, with information updating
Specificity: older adults receiving
home health services
(Continued)
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Table 1 | Continued
Reference Settings Population Subgroups of serum
25-hydroxyvitamin D
Association with cognitive
scale scores?
Wilkins et al.
(2009)
Location: Washington, DC,
USA (38.9°N)
Community-dwellers <20 Versus ≥20 ng/mL No, with global cognitive
performanceN =60
Mean age: 75.0±8.2 years
50.0% Black
Specificity: either cognitively normal or
mildly impaired cognition, without
vitamin D supplementation
Hansen et al.
(2011)
Location: Bergen, Norway
(60.4°N)
N =25, 100% men <20 Versus ≥20 ng/mL No, with information
processing speed
Yes, with information updating
Mean age: 34.6±9.4 years
Specificity: only middle-aged men
incarcerated in a Norwegian prison
Menant et al.
(2012); Memory
and Aging Study
Location: Sydney, NSW,
Australia (33.5°S)
Community-dwellers
N =463, 53.4% women
Mean age: 78.0±4.6 years
≤20 Versus >20 ng/mL No, with global cognitive
performance
No, with information
processing speed
Yes, with mental shifting
THRESHOLD 30ng/mL
Llewellyn et al.
(2011); NHANES
III
Location: USA
(25.5°N – 47.3°N)
Community-dwellers
N =3325, 55.2% women
Mean age: 73.7±10.9 years
7.6% Black
Specificity: only older adults
<10 Versus ≥30 ng/mL Yes, with global cognitive
performance
Yes, with information
processing speed
Yes, with information updating
Yes, with episodic memory
Llewellyn et al.
(2010); InCHIANTI
study
Location: Italy (Greve in
Chianti, 43.6°N; Bagno a
Ripoli, 43.8°N)
Community-dwellers <10 Versus ≥30 ng/mL Yes, with global cognitive
performance
Yes, with information
processing speed
Yes, with mental shifting
N =858, 49.4% women
Mean age at baseline: 73.9 years
Caucasian
Specificity: older adults from a
geographically confined area
Slinin et al. (2012);
SOF study
Location: USA (Baltimore,
MD, 39.3°N; Pittsburgh, PA,
40.4°N; Portland, OR, 45.6°N;
Minneapolis, MN, 46.9°N)
Community-dwellers <10 Versus ≥30 ng/mL Yes, with global cognitive
performance
Yes, with mental shifting
N =5692, 100% women
Mean age at baseline: 76.6±4.7 years
Caucasian
Specificity: only older women
vitamin D supplementation in clinical rou-
tine to prevent both skeletal and non-
skeletal adverse consequences of hypovi-
taminosis D. Third, this finding is inter-
esting for the conduct of future clinical
trials testing the cognitive efficacy of vit-
amin D supplements. Since it is useless to
give vitamin D supplements to people who
already have a satisfactory rate (Annweiler
and Beauchet, 2013), it appears appropri-
ate to include in future trials only older
participants who have 25OHD concen-
trations <10 ng/mL. Conversely, including
participants with higher initial rates might
mask the cognitive effects of supplementa-
tion (if any). What is more, it is legitimate
to propose a supplement plan designed
to achieve a final 25OHD concentration
>30 ng/mL.
CONCLUSION
In conclusion, older adults commonly
have low serum vitamin D concentrations.
For clinicians, it is useful to determine
the level of vitamin D required to pre-
vent the development of diseases. Regard-
ing cognition, existing literature provides
evidence that the threshold of 25OHD
associated with cognitive disorders is some-
where around 10 ng/mL. Unfortunately
no study has tested yet the three classi-
cal 25OHD thresholds simultaneously in
relation to cognition. Prospective multi-
center population-based cohort studies
are desirable to address this issue specif-
ically with a satisfactory level of evi-
dence.
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